Amgen, Inc. (AMGN) Short Interest Up 20.2% in February

Amgen, Inc. (NASDAQ:AMGN) saw a large growth in short interest in the month of February. As of February 28th, there was short interest totalling 10,361,375 shares, a growth of 20.2% from the February 15th total of 8,618,230 shares. Currently, 1.4% of the shares of the company are short sold. Based on an average trading volume of 4,385,991 shares, the days-to-cover ratio is currently 2.4 days.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Wednesday, February 14th. The stock was sold at an average price of $174.18, for a total transaction of $265,624.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold a total of 4,575 shares of company stock valued at $838,064 over the last ninety days. 0.19% of the stock is owned by insiders.

How to Become a New Pot Stock Millionaire

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in Amgen by 4.8% during the second quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Amgen by 0.9% in the second quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock valued at $8,981,266,000 after purchasing an additional 489,720 shares during the period. BlackRock Inc. grew its position in shares of Amgen by 1.9% in the second quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock valued at $8,516,980,000 after purchasing an additional 909,689 shares during the period. Bank of New York Mellon Corp grew its position in shares of Amgen by 1.7% in the third quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock valued at $1,522,551,000 after purchasing an additional 140,117 shares during the period. Finally, Geode Capital Management LLC grew its position in shares of Amgen by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 8,110,133 shares of the medical research company’s stock valued at $1,407,552,000 after purchasing an additional 199,838 shares during the period. 79.53% of the stock is owned by institutional investors.

NASDAQ AMGN traded down $4.43 during mid-day trading on Monday, hitting $166.05. The stock had a trading volume of 4,756,745 shares, compared to its average volume of 5,220,746. Amgen has a 52-week low of $152.16 and a 52-week high of $201.23. The company has a market capitalization of $122,841.44, a P/E ratio of 13.20, a PEG ratio of 2.09 and a beta of 1.36. The company has a debt-to-equity ratio of 1.35, a current ratio of 5.49 and a quick ratio of 5.17.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share for the quarter, missing the consensus estimate of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The firm had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same period in the previous year, the business earned $2.89 earnings per share. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. research analysts expect that Amgen will post 13.25 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 8th. Investors of record on Thursday, May 17th will be paid a $1.32 dividend. This represents a $5.28 annualized dividend and a yield of 3.18%. The ex-dividend date is Wednesday, May 16th. Amgen’s payout ratio is currently 41.97%.

Amgen declared that its board has authorized a stock repurchase program on Thursday, February 1st that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire shares of its stock through open market purchases. Shares buyback programs are usually a sign that the company’s board believes its stock is undervalued.

A number of analysts have weighed in on AMGN shares. Oppenheimer reaffirmed a “buy” rating and set a $205.00 price objective on shares of Amgen in a research report on Tuesday, January 30th. Argus raised Amgen from a “hold” rating to a “buy” rating and increased their price objective for the stock from $192.33 to $220.00 in a research report on Tuesday, January 23rd. Piper Jaffray reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Mizuho set a $192.00 price target on Amgen and gave the company a “buy” rating in a report on Thursday, December 28th. Finally, Goldman Sachs cut Amgen from a “conviction-buy” rating to a “buy” rating in a report on Friday, December 15th. Two investment analysts have rated the stock with a sell rating, fourteen have given a hold rating and eleven have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $191.26.

WARNING: “Amgen, Inc. (AMGN) Short Interest Up 20.2% in February” was originally reported by Enterprise Leader and is owned by of Enterprise Leader. If you are viewing this piece on another site, it was copied illegally and republished in violation of US & international copyright & trademark law. The correct version of this piece can be accessed at https://theenterpriseleader.com/2018/04/02/amgen-inc-amgn-sees-large-increase-in-short-interest.html.

Amgen Company Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply